Imatinib Mesylate in Treating Patients With Myelofibrosis
Stopped early · Phase 2
Conditions studied: Chronic Myeloproliferative Disorders
In brief
RATIONALE: Imatinib mesylate may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. PURPOSE: This phase II trial is studying the side effects of imatinib mesylate and how well it works in treating patients with myelofibrosis.
Key facts
- Study ID
- NCT00245128
- Run by
- OHSU Knight Cancer Institute
- People needed
- 10
- Starts
- 2005-08-01
- Expected to finish
- 2011-10-01
- Last updated by the study team
- 2012-01-13
Who can join
Age: 18 and older. Sex: any. Healthy volunteers: not accepted.
Where it is running
- OHSU Knight Cancer Institute — Portland, Oregon, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.